Definium Therapeutics, Inc. (NASDAQ:DFTX) Given Average Rating of “Buy” by Analysts

Definium Therapeutics, Inc. (NASDAQ:DFTX) has been given a consensus recommendation of “Buy” by the seventeen research firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, fourteen have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $47.0769.

DFTX has been the topic of a number of research reports. HC Wainwright increased their price target on Definium Therapeutics from $55.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Stifel Nicolaus set a $30.00 price objective on Definium Therapeutics and gave the stock a “buy” rating in a research note on Thursday, April 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Definium Therapeutics in a research note on Tuesday, April 21st. Oppenheimer set a $60.00 price objective on Definium Therapeutics and gave the stock an “outperform” rating in a research note on Monday. Finally, Robert W. Baird boosted their price objective on Definium Therapeutics from $37.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday.

Definium Therapeutics Trading Up 6.3%

Shares of NASDAQ DFTX opened at $44.79 on Friday. The stock’s 50 day moving average price is $24.13 and its two-hundred day moving average price is $19.18. Definium Therapeutics has a 52-week low of $6.40 and a 52-week high of $47.01. The stock has a market capitalization of $4.47 billion, a P/E ratio of -17.99 and a beta of 2.37. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.15.

Definium Therapeutics (NASDAQ:DFTX) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.23). On average, analysts anticipate that Definium Therapeutics will post -2.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Definium Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in DFTX. Commodore Capital LP lifted its position in shares of Definium Therapeutics by 10.5% during the 2nd quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock worth $32,450,000 after purchasing an additional 475,000 shares during the last quarter. Orbimed Advisors LLC acquired a new stake in Definium Therapeutics during the third quarter valued at approximately $4,337,000. Rosalind Advisors Inc. boosted its holdings in shares of Definium Therapeutics by 78.6% in the 3rd quarter. Rosalind Advisors Inc. now owns 750,000 shares of the company’s stock worth $8,842,000 after acquiring an additional 330,000 shares in the last quarter. Two Sigma Investments LP boosted its holdings in shares of Definium Therapeutics by 424.9% in the 3rd quarter. Two Sigma Investments LP now owns 296,443 shares of the company’s stock worth $3,495,000 after acquiring an additional 239,965 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Definium Therapeutics by 11.0% during the 3rd quarter. Vanguard Group Inc. now owns 2,012,874 shares of the company’s stock worth $23,732,000 after buying an additional 198,878 shares in the last quarter. 27.91% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium reported a Phase 3 win for DT120, which appears to be the main catalyst behind the recent rally and reinforced optimism around its psychiatric and neurological disorder pipeline.
• Positive Sentiment: JonesTrading raised its price target on DFTX to $74 from $61 and reiterated a buy rating, signaling continued analyst confidence after the trial update.
• Positive Sentiment: Lifesci Capital nudged up its earnings estimates for FY2026 and Q4 2026, suggesting slightly improved expectations for the company’s financial outlook.
• Neutral Sentiment: The biotech sector also got a lift from a strong rebound in the index underlying the SBIO ETF after its rebalance, which may have provided some supportive industry sentiment.
• Negative Sentiment: Definium priced and then closed a large upsized public offering, ultimately raising about $805 million and issuing more than 23.6 million shares, which increases dilution and can pressure the stock even when the capital raise strengthens the balance sheet. Article Title

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.